Market closed
Cartesian Therapeutics/$RNAC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cartesian Therapeutics
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
Ticker
$RNAC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
38
RNAC Metrics
BasicAdvanced
$496M
Market cap
-
P/E ratio
-$23.08
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$496M
52-week high
$41.87
52-week low
$11.67
Average daily volume
139K
Financial strength
Current ratio
10.705
Quick ratio
10.512
Long term debt to equity
1,579.92
Total debt to equity
1,948.271
Management effectiveness
Return on assets (TTM)
-10.95%
Return on equity (TTM)
-7,029.26%
Valuation
Price to revenue (TTM)
4.922
Price to book
612.35
Price to tangible book (TTM)
-2.33
Price to free cash flow (TTM)
-4.874
Growth
Revenue change (TTM)
-62.40%
What the Analysts think about RNAC
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cartesian Therapeutics stock.
RNAC Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RNAC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RNAC News
AllArticlesVideos
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewsWire·3 days ago
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial
GlobeNewsWire·3 weeks ago
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cartesian Therapeutics stock?
Cartesian Therapeutics (RNAC) has a market cap of $496M as of December 21, 2024.
What is the P/E ratio for Cartesian Therapeutics stock?
The price to earnings (P/E) ratio for Cartesian Therapeutics (RNAC) stock is 0 as of December 21, 2024.
Does Cartesian Therapeutics stock pay dividends?
No, Cartesian Therapeutics (RNAC) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Cartesian Therapeutics dividend payment date?
Cartesian Therapeutics (RNAC) stock does not pay dividends to its shareholders.
What is the beta indicator for Cartesian Therapeutics?
Cartesian Therapeutics (RNAC) does not currently have a Beta indicator.